NCT03161288View on ClinicalTrials.gov

A Study of KY1005 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 29, 2017

Primary Completion Date

March 30, 2018

Study Completion Date

March 30, 2018

Conditions
Immune System Diseases
Interventions
DRUG

KY1005

A human anti-OX40 ligand monoclonal antibody

DRUG

Placebo

Matched placebo

Trial Locations (1)

Unknown

Centre for Human Drug Research, Leiden

All Listed Sponsors
lead

Kymab Limited

INDUSTRY

NCT03161288 - A Study of KY1005 in Healthy Volunteers | Biotech Hunter | Biotech Hunter